Recent progress in the development of coumarin derivatives as potent anti-HIV agents

Medicinal Research Reviews

Volumn 23, Issue 3, 2003, Pages 322-345

  Yu, Donglei ^a   Suzuki, Madoka ^a   Xie, Lan ^a   Morris Natschke, Susan L ^a   Lee, Kuo Hsiung ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Anti HIV coumarins; Calanolides; DCK analogs; Inophyllums; Khellactone; Tetracyclic dipyranocoumarins

Indexed keywords

ANGELICIN; CALANOLIDE A; CALANOLIDE B; CORIANDRIN; COUMARIN DERIVATIVE; DI O ACETYL 3 CARBOXYLKHELLACTONE DERIVATIVE; DICAMPHANOYLKHELLACTONE DERIVATIVE; DIHYDROCALANOLIDE B; FUROCOUMARIN; GLYCOUMARIN; INOPHYLLUM; INOPHYLLUM B; INOPHYLLUM P; INTEGRASE INHIBITOR; KHELLACTONE; KHELLACTONE COUMARIN DERIVATIVE; LIPOPYRANOCOUMARIN; PD 099560; PHENPROCOUMON; PROTEINASE INHIBITOR; PSORALEN; SOULATTROLIDE; STILBENE DERIVATIVE; SUKSDORFIN; TETRACYCLIC DIPYRANOCOUMARIN DERIVATIVE; U 34445; U 345401; U 35122; U 35401; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CHEMICAL MODIFICATION; CHIRALITY; CIS TRANS ISOMERISM; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG SOLUBILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOMERISM; LYMPHOCYTE CULTURE; MOLECULAR MODEL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; STEREOCHEMISTRY; STOICHIOMETRY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; VIRUS ADSORPTION; VIRUS INHIBITION; VIRUS REPLICATION; X RAY CRYSTALLOGRAPHY; X RAY DIFFRACTION;

ANTI-HIV AGENTS; COUMARINS; DRUG DESIGN; HIV; HUMANS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037404483     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.10034     Document Type: Review

References (76)

1. Kanazawa S, Matija PB. Repression of MHC determinants in HIV infection. Microbes Infect 2001;3:467-473.
2. Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, Saxon A. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men. N Engl J Med 1981;305: 1425-1431.
3. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-871.
4. Gallo RC, Sarin PS, Gelmann EP, Robert-Guroff M, Richardson E, Kalyanaraman VS, Mann D, Sidhu GD, Stahl RE, Zolla-Pazner S, Leibowitch J, Popovic M. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983;220:865-867.
5. UNAIDS and WHO. AIDS epidemic update, Under Embargo. 2001.
6. Moore JP, Stevenson M. New targets for inhibitors of HIV-1 replication. Nat Rev Mol Cell Biol 2000;1: 40-49.
7. Miller MD, Hazuda DJ. New antiretroviral agents: Looking beyond protease and reverse transcriptase. Curr Opin Microbiol 2001;4:535-539.
8. FDA. Antiretroviral drugs approved by FDA for HIV. Information may be found at internet at: http:// www.fda.gov/oashi/aids/virals.html/
9. FDA. FDA talk paper: FDA approves Viread for HIV-1 infection. Information may be found at internet at: http://www.fda.gov/bbs/topics/ANSWERS/2001/ANS01111.html/
10. Swanstrom R, Erona J. Human immunodeficiency virus type-1 protease inhibitors: Therapeutic successes and failures, suppression and resistance. Pharmacol Ther 2000;86:145-170.
11. Loveday C. Nucleoside reverse transcriptase inhibitor resistance. JAIDS 2001;26:S1O-S24.
12. Pellegrin I, Garrigue I, Caumont A, Pellegrin JL, Merel P, Schrive MH, Bonot P, Fleury H. Persistence of zidovudine-resistance mutations in HIV-1 isolates from patients removed from zidovudine therapy for at least 3 years and switched to a stavudine-containing regimen. AIDS (London, UK) 2001;15:1071-1073.
13. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, Hirschel B, Vernazza P, Francioli P, Greub G, Flepp M, Telenti A. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001;358:1322-1327.
14. Vlietinck AJ, De Bruyne T, Apers S, Pieters LA. Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection. Planta Med 1998;64:97-109.
15. Hudson J, Towrs GHN. Phytomedicines as antivirals. Drugs Future 1999;24:295-320.
16. Yang SS, Cragg GM, Newman DJ, Bader JP. Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics Program. J Nat Prod 2001;64:265-277.
17. Nishino H, Okuyama T, Takata M, Shibata S, Tokuda H, Takayasu J, Hasegawa T, Nishino A, Ueyama H, Iwashima A. Studies on the anti-tumor-promoting activity of naturally occurring substances. IV. Pd-II [(+)anomalin, (+)praeruptorin B], a seselin-type coumarin, inhibits the promotion of skin tumor formation by 12-0-tetradecanoylphorbol-13-acetate in 7,12-dimethylbenz[a]anthracene-initiated mice. Carcinogenesis (London) 1990;11:1557-1561.
18. Tsai IL, Wun MF, Teng CM, Ishikawa T, Chen IS. Anti-platelet aggregation constituents from Formosan Toddalia asiatica. Phytochemistry 1998;48:1377-1382.
19. Lee TT, Kashiwada Y, Huang L, Snider J, Cosentino M, Lee KH. Suksdorfin: An anti-HIV principle from Lomatium suksdorfii, its structure- activity correlation with related coumarins, and synergistic effects with anti-AIDS nucleosides. Bioorg Med Chem Lett 1994;2:1051-1056.
20. Huang L, Kashiwada Y, Cosentino LM, Fan S, Lee KH. 3′,4′-di-O-(-)-camphanoyl-(+)-cis-khellactone and related compounds: A new class of potent anti-HIV agents. Bioorg Med Chem Lett 1994;4:593-598.
21. Huang L, Kashiwada Y, Cosentino LM, Fan S, Chen CH, McPhail AT, Fujioka T, Mihashi K, Lee KH. Anti-AIDS Agents. 15. Synthesis and anti-HIV activity of dihydroseselins and related analogs. J Med Chem 1994;37:3947-3955.
22. Xie L, Crimmins MT, Lee KH. Anti-AIDS agents. 22. Asymmetric synthesis of 3′,4′-di-O-(-)-camphanoyl-(+)-cis-khellactone (DCK), a potent anti-HIV agent. Tetrahedron Lett 1995;36:4529-4532.
23. Mehltretter GM, Dobler C, Sundermeier U, Beller M. An improved version of the sharpless asymmetric dihydroxylation. Tetrahedron Lett 2000;41:8083-8087.
24. Kolb HC, VanNieuwenhze MS, Sharpless KB. Catalytic asymmetric dihydroxylation. Chem Rev (Washington DC, US) 1994;94:2483-2547.
25. Xia Y, Yang ZY, Brossi A, Lee KH. Asymmetric solid-phase synthesis of (3′R,4′R)-di-O-cis-acyl 3-carboxyl khellactones. Org Lett 1999;1:2113-2115.
26. Xie L, Takeuchi Y, Cosentino LM, McPhail AT, Lee KH. Anti-AIDS agents. 42. Synthesis and anti-HIV activity of disubstituted (3′R,4′R)-3′,4′-di-O-(S)-camphanoyl-(+)-cis- khellactone analogues. J Med Chem 2001;44:664-671.
27. Xie L, Takeuchi Y, Cosentino LM, Lee KH. Anti-AIDS agents. 37.synthesis and structure-activity relationships of (3′R,4′R)-(+)-cis-khellactone derivatives as novel potent anti-HIV agents. J Med Chem 1999;42:2662-2672.
28. Yang ZY, Xia Y, Xia P, Cosentino LM, Lee KH. Anti-AIDS agents. 31. Synthesis and anti-HIV activity of 4-substituted 3′,4′-di-O-(-)-camphanoyl-(+)-cis-khellactone (DCK) thiolactone analogs. Bioorg Med Chem Lett 1998;8:1483-1486.
29. Xie L, Takeuchi Y, Cosentino LM, Lee KH. Anti-AIDS agents 33 synthesis and anti-HIV activity of monomethyl substituted 3′,4′-di-O-(-)-camphanoyl-(+)-cis-khellactone (DCK) analogs. Bioorg Med Chem Lett 1998;8:2151-2156.
30. Takeuchi Y, Xie L, Cosentino LM, Lee KH. Anti-AIDS agents - XXVIII. Synthesis and anti-HIV activity of methoxy substituted 3′,4′-di-O-(-)-camphanoyl-(+)-cis-khellactone (DCK) analogs. Bioorg Med Chem Lett 1997;7:2573-2578.
31. Yang ZY, Xia Y, Xia P, Brossi A, Cosentino LM, Lee KH. Anti-AIDS agents part 41: Synthesis and anti-HIV activity of 3′,4′-di-O-(-)-camphanoyl-(+)-cis-khellactone (DCK) lactam analogues. Bioorg Med Chem Lett 2000;10:1003-1005.
32. Xie L, Allaway G, Wild C, Kilgore N, Lee KH. Anti-AIDS agents part 47. Synthesis and anti-HIV activity of 3-substituted 3′,4′-di-O-(S)-camphanoyl-(3′R,4′R)-(+)-cis- khellactone derivatives. Bioorg Med Chem Lett 2001;11:2291-2293.
33. Kashman Y, Gustafson KR, Fuller RW, Cardellina JH II, McMahon JB, Currens MJ, Buckheit RW, Jr., Hughes SH, Cragg GM, Boyd MR. HIV inhibitory natural products. Part 7. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J Med Chem 1992;35:2735-2743.
34. Dharmaratne HRW, Wanigasekera WMAP, Mata-Greenwood E, Pezzuto JM. Inhibition of human immunodeficiency virus type 1 reverse transcriptase activity by cordatolides isolated from Calophyllum cordato-oblongum. Planta Med 1998;64:460-461.
35. Patil AD, Freyer AJ, Eggleston DS, Haltiwanger RC, Bean MF, Taylor PB, Caranfa MJ, Breen AL, Bartus HR. The inophyllums, novel inhibitors of HIV-1 reverse transcriptase isolated from the Malaysian tree, Calophyllum inophyllum Linn. J Med Chem 1993;36:4131-4138.
36. Spino C, Dodier M, Sotheeswaran S. Anti-HIV coumarins from Calophyllum seed oil. Bioorg Med Chem Lett 1998;8:3475-3478.
37. McKee TC, Covington CD, Fuller RW, Bokesch HR, Young S, Cardellina JH II, Kadushin MR, Soejarto DD, Stevens PF, Cragg GM, Boyd MR. Pyranocoumarins from tropical species of the genus Calophyllum: A chemotaxonomic study of extracts in the National Cancer Institute collection. J Nat Prod 1998;61:1252-1256.
38. De Clercq E. Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Med Res Rev 2000;20:323-349.
39. Patil AD, Hertzberg RP, Dreyer GB, Freyer AJ, Westley JW, Chenera B, West ML. Coumarin derivatives as retroviral inhibitors. 1994;PCT: WO9414789.
40. Galinis DL, Fuller RW, McKee TC, Cardellina JH II, Gulakowski RJ, McMahon JB, Boyd MR. Structure-activity modifications of the HIV-1 inhibitors (+)-calanolide A and (-)-calanolide B. J Med Chem 1996;39:4507-4510.
41. Zembower DE, Liao S, Flavin MT, Xu ZQ, Stup TL, Buckheit RWJ, Khilevich A, Mar AA, Sheinkman AK. Structural analogs of the calanolide anti-HIV agents. Modification of the trans-10, 11-dimethyldihydropyran-12-ol ring (ring C). J Med Chem 1997;40:1005-1017.
42. Xu ZQ, Buckheit RW, Jr., Stup TL, Flavin MT, Khilevich A, Rizzo JD, Lin L, Zembower DE. In vitro antihuman immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI. Bioorg Med Chem Lett 1998;8:2179-2184.
43. Pengsuparp T, Serit M, Hughes SH, Soejarto DD, Pezzuto JM. Specific inhibition of human immunodeficiency virus type 1 reverse transcriptase mediated by soulattrolide, a coumarin isolated from the latex of Calophyllum teysmannii. J Nat Prod 1996;59:839-842.
44. Currens MJ, Mariner JM, McMahon JB, Boyd MR. Kinetic analysis of inhibition of human immunodeficiency virus type-1 reverse transcriptase by calanolide A. J Pharmacol Exp Ther 1996;279:652-661.
45. Taylor PB, Culps JS, Debouk C, Johnson RK. Kinetic and mutational analysis of human immunodeficiency virus type I reverse transcriptase inhibition by inophyllums, a novel class of non-nucleotide inhibitors. J Biol Chem 1994;269:6325-6331.
46. Buckheit RW, Jr., White EL, Eliakas-Boltz V, Russell J, Stup TL, Kinjerski TL, Osterling MC, Weigand A, Bader JP. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide. Antimicrob Agents Chemother 1999;43: 1827-1834.
47. Buckheit RW, Jr., Russell JD, Xu ZQ, Flavin M. Anti-HIV-1 activity of calanolides used in combination with other mechanistically diverse inhibitors of HIV-1 replication. Antiviral Chem Chemother 2000;11: 321-327.
48. Currens MJ, Gulakowski RJ, Mariner JM, Moran RA, Buckheit RW, Jr., Gustafson KR, McMahon JB, Boyd MR. Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1. J Pharmacol Exp Ther 1996;279:645- 651.
49. Xu ZQ, Hollingshead MG, Borgel S, Elder C, Khilevich A, Flavin MT. In vivo anti-HIV activity of(+)-calanolide A in the hollow fiber mouse model. Bioorg Med Chem Lett 1999;9:133-138.
50. Newman RA, Chen W, Madden TL. Pharmaceutical properties of related calanolide compounds with activity against human immunodeficiency virus. J Pharm Sci 1998;87:1077-1080.
51. Ishikawa T, Oku Y, Tanaka T, Kumamoto T. An approach to anti-HIV-1 active calophyllum coumarin synthesis: An enantioselective construction of 2,3-dimethyl-4-chromanone ring by quinine-assisted intramolecular Michael-type addition. Tetrahedron Lett 1999;40:3777-3780.
52. Rehder KS, Kepler JA. Total synthesis of ±-calanolide A. Synth Commun 1996;26:4005-4021.
53. Flavin MT, Rizzo JD, Khilevich A, Kucherenko A, Sheinkman AK, Vilaychack V, Lin L, Chen W, Mata E. Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of ±-calanolide A and its enantiomers. J Med Chem 1996;39:1303-1313.
54. Tanaka T, Kumamoto T, Ishikawa T. Enantioselective total synthesis of anti HIV-1 active (+)-calanolide A through a quinine-catalyzed asymmetric intramolecular oxo-Michael addition. Tetrahedron Lett 2000;41: 10229-10232.
55. Creagh T, Ruckle JL, Tolbert DT, Giltner J, Eiznhamer DA, Dutta B, Flavin MT, Xu ZQ. Safety and pharmacokinetics of single doses of (+)-calanolide A, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects. Antimicrob Agents Chemother 2001;45:1379-1386.
56. Sherer R, Dutta B, Anderson R, Laudetteaboulhab J. A phase IB study of (+)-calanolide A in HIV-1-infected, antiretroviral therapy naive patients. 7th Conference on Retroviruses and Opportunistic Infections. 2000.
57. Sarawak Medichem Pharmaceuticals, Inc. Calanolide A development plan. Information may be found at: www.sarawak-medichem.com/cala/dev.html/
58. Tummino PJ, Ferguson D, Hupe D. Competitive inhibition of HIV-1 protease by warfarin derivatives. Biochem Biophys Res Commun 1994;201:290-294.
59. Lunney EA, Hagen SE, Domagala JM, Humblet C, Kosinski J, Tait BD, Warmus JS, Wilson M, Ferguson D, Hupe D, Tummino PJ, Baldwin ET, Bhat TN, Liu B, Erickson JW. A novel nonpeptide HIV-1 protease inhibitor: Elucidation of the binding mode and its application in the design of related analogs. J Med Chem 1994;37:2664-2677.
60. Janakiraman MN, Mullen CR, Strohback JW. Crystallography and the design of non-peptidic HIV protease inhibitors; 4-hydroxycoumarins, 4-hydroxy-2-pyrones, and tetronic acid. American Crystallographic Association Annual Meeting. 1995.
61. Chong KT, Pagano PJ. In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrob Agents Chemother 1997;41:2367-2373.
62. Thaisrivongs S, Strohbach JW. Structure-based discovery of Tipranavir disodium (PNU-140690E): A potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Biopolymers 1999;51:51-58.
63. Skulnick HI, Johnson PD, Howe WJ, Tomich PK, Chong KT, Watenpaugh KD, Janakiraman MN, Dolak LA, McGrath JP. Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors. J Med Chem 1995;38:4968-4971.
64. d'Angelo J, Mouscadet JF, Desmaele D, Zouhiri F, Leh H. HIV-1 integrase: The next target for AIDS therapy? Pathol Biol 2001;49:237-246.
65. Mazumder A, Wang S, Neamati N, Nicklaus M, Sunder S, Chen J, Milne GWA, Rice WG, Burke TR, Jr., Pommier Y. Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease. J Med Chem 1996;39:2472-2481.
66. Zhao H, Neamati N, Hong H, Mazumder A, Wang S, Sunder S, Milne GWA, Pommier Y, Burke TR, Jr. Coumarin-based inhibitors of HIV integrase. J Med Chem 1997;40:242-249.
67. Martyanov IV, Zakharova OD, Sottofattori E, Pyshnyi DV, Yurchenko EY, Babbi P, Mazzei M, Balbi A, Andreola ML, Litvak S, Tarrago-Litvak L, Nevinsky GA. Interaction of oligonucleotides conjugated to substituted chromones and coumarins with HIV-1 reverse transcriptase. Antisense Nucleic Acid Drug Dev 1999;9:473-480.
68. Miolo G, Tomanin R, De Rossi A, Dall'Acqua F, Zacchello F, Scarpa M. Antiretroviral activity of furocoumarins plus UVA light detected by a replication-defective retrovirus. J Photochem Photobiol B Biol 1994;26:241-247.
69. Hudson JB, Graham EA, Harris L, Ashwood-Smith MJ. The unusual UVA-dependent antiviral properties of the furoisocoumarin, coriandrin. Photochem Photobiol 1993;57:491-496.
70. Rice WG, Schaeffer CA, Harten B, Villinger F, South TL, Summers MF, Henderson LE, Bess JW, Jr., Arthur LO. Inhibition of HIV-1 infectivity by zinc-ejecting aromatic C-nitroso compounds. Nature (London) 1993;361:473-475.
71. Yamagoe S, Kohda T, Oishi M. Poly(ADP-ribose) polymerase inhibitors suppress UV-induced human immunodeficiency virus type 1 gene expression at the posttranscriptional level. Mol Cell Biol 1991; 11:3522-3527.
72. Althaus IW, Franks KM, Langley KB, Kezdy FJ, Peterson T, Baxser SE, Decker DE, Dolak LA, Ulrich RG, Reusser F. The amphiphilic properties of novenamines determine their activity as inhibitors of HIV-1 RNase H. Experientia 1996;52:329-335.
73. Wu TS, Tsang ZJ, Wu PL, Lin FW, Li CY, Teng CM, Lee KH. New constituents and antiplatelet aggregation and anti-HIV principles of Artemisia capillaris. Bioorg Med Chem 2001;9:77-83.
74. Zhou P, Takaishi Y, Duan H, Chen B, Honda G, Itoh M, Takeda Y, Kodzhimatov OK, Lee KH. Coumarins and bicoumarin from Ferula sumbul: Anti-HIV ctivity and inhibition of cytokine release. Phytochemistry 2000;53:689-697.
75. Shikishima Y, Takaishi Y, Honda G, Ito M, Takeda Y, Kodzhimatov OK, Ashurmetov O, Lee KH. Chemical constituents of Prangos tschimganica; structure elucidation and absolute configuration of coumarin and furanocoumarin derivatives with anti-HIV activity. Chem Pharm Bull 2001;49:877-880.
76. Hatano T, Yasuhara T, Miyamoto K, Okuda T. Anti-human immunodeficiency virus phenolics from licorice. Chem Pharm Bull 1988;36:2286-2288.